Andrewm457 (a well respected poster and researcher) wrote this about the purchase a while back :
"re: Ann: Alchemia Licenses novel FAK Inhibito...
Don't know how I missed this ann - oops!
I can't be certain due to the vagueness of just saying "FAK inhibitors", but if I'm following ACL's reasoning here* this acquisition makes sense given the nature of the HyACT platform.
Good luck all holders.
* My guess would be that this is an attempt to source a technology (FAK inhibition) which would enable ACL to tackle any potential issues with HA-promoted motility in CD44+ tumour cells in earlier stage cancers in-house... but I'd like some more details!"
Andrewm457 (a well respected poster and researcher) wrote this...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable